HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
December 05, 2022 06:30 ET
|
HilleVax, Inc.
BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported results...
HilleVax to Participate in November Investor Conferences
November 10, 2022 18:30 ET
|
HilleVax, Inc.
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 10, 2022 16:05 ET
|
HilleVax, Inc.
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial...
HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series
September 01, 2022 17:18 ET
|
HilleVax, Inc.
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
HilleVax Announces Positive Recommendation from Safety Data Monitoring Committee for NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
August 31, 2022 07:00 ET
|
HilleVax, Inc.
Enrollment of remaining subjects in NEST-IN1 has resumed Immunogenicity results from the first 200 subjects expected in Q4 2022 BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc....
HilleVax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum
August 15, 2022 07:00 ET
|
HilleVax, Inc.
BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate
July 20, 2022 16:05 ET
|
HilleVax, Inc.
Pan-Ig and HBGA blocking antibody responses persisted to year 5 No adverse events deemed related to HIL-214 BOSTON, July 20, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a...
HilleVax Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
June 08, 2022 16:01 ET
|
HilleVax, Inc.
Initiated Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants (NOR-212) Completed Upsized Initial Public Offering Raising...
HilleVax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 03, 2022 16:00 ET
|
HilleVax, Inc.
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the...
HilleVax Announces Initiation of Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants
May 02, 2022 07:00 ET
|
HilleVax, Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, reported today...